Form 4: Mineralys Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, Inc., sold 2,170 shares of common stock on August 10, 2026 for $27.09 per share.
Summary
- Option exercise/conversion: acquired 2,170 Common Stock at $16.00 ($34,720) on August 10, 2026; holds 53,554 after (Direct).
- Open-market sale: disposed of 2,170 Common Stock at $27.09 ($58,785) on August 10, 2026; holds 51,384 after (Direct).
- Option exercise/conversion: disposed of 2,170 Stock Option on August 10, 2026; holds 13,024 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $58,785 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
David Malcom Rodman — Officer (Chief Medical Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-10 | Option exercise/conversion | Common Stock | 2,170 | $16 | $34.7K | 53,554 |
| 2026-08-10 | Open-market sale | Common Stock | 2,170 | $27 | $58.8K | 51,384 |
| 2026-08-10 | Option exercise/conversion | Stock Option | 2,170 | — | — | 13,024 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-10 | Option exercise/conversion (2,170 shares) |
| 2026-08-10 | Open-market sale (2,170 shares) |
| 2026-08-10 | Option exercise/conversion (2,170 shares) |
Keywords
insider transaction, Form 4, MLYS, Mineralys Therapeutics, Inc., bearish, David Malcom Rodman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.